Loading cancer entity…
Loading cancer entity…
Clinical trials
4,036 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (701)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06371573 | Ultrasound Examination for Spleen Volume Evaluation in Myeloproliferative Neoplasms | completed | — | 45 | Federico II UniversityOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT04202003 | A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) | completed | Phase 1 / Phase 2 | 105 | TJ Biopharma Co., Ltd.INDUSTRY |
| 1 |
| Apr 15, 2024 |
| clinicaltrials |
| NCT02340884 | A Pilot RCT of the PRISM Intervention for AYAs With Cancer | completed | Phase 2 | 92 | Seattle Children's HospitalOTHER | 1 | Apr 9, 2024 | clinicaltrials |
| NCT04666025 | SARS-CoV-2 Donor-Recipient Immunity Transfer | completed | — | 26 | City of Hope Medical CenterOTHER | 1 | Apr 8, 2024 | clinicaltrials |
| NCT03959241 | TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)(1703/1801) | completed | Phase 3 | 431 | Medical College of WisconsinOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT01578109 | Sorafenib Tosylate Before and After Donor Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia | completed | Phase 1 | 51 | National Cancer Institute (NCI)NIH | 1 | Apr 2, 2024 | clinicaltrials |
| NCT01588015 | Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant | completed | Phase 1 | 36 | City of Hope Medical CenterOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT05421091 | Special Drug Use-results Surveillance of Scemblix Tablets | completed | — | 550 | Novartis PharmaceuticalsINDUSTRY | 1 | Mar 27, 2024 | clinicaltrials |
| NCT01595295 | Registry on Hypomethylating Agents in Myeloid Neoplasms | completed | — | 1,500 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 2 | Mar 25, 2024 | clinicaltrials |
| NCT02081378 | A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL | completed | Phase 1 | 326 | Novartis PharmaceuticalsINDUSTRY | 10 | Mar 18, 2024 | clinicaltrials |
| NCT04767802 | PTG-300 in Patients With Polycythemia Vera and Elevated Hematocrit(PACIFIC) | completed | Phase 2 | 20 | Protagonist Therapeutics, Inc.INDUSTRY | 2 | Mar 18, 2024 | clinicaltrials |
| NCT01858740 | Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children | completed | Phase 2 | 20 | Fred Hutchinson Cancer CenterOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT04384848 | The EMPATHY Pilot Study | completed | N/A | 94 | Northwestern UniversityOTHER | 2 | Mar 4, 2024 | clinicaltrials |
| NCT00235560 | Rapamycin in Combination With Low-dose Aracytin in Elderly Acute Myeloid Leukemia Patients(LAM-RAPA) | completed | Phase 2 | 50 | University Hospital, ToulouseOTHER | 1 | Feb 29, 2024 | clinicaltrials |
| NCT02013648 | Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™) | completed | Phase 3 | 204 | University of UlmOTHER | 2 | Feb 23, 2024 | clinicaltrials |
| NCT03564288 | Study to Find a Safe and Effective Dose of SKI-G-801 in the Treatment of Patients With Acute Myeloid Leukemia (AML) | completed | Phase 1 | 14 | Oscotec Inc.INDUSTRY | 1 | Feb 21, 2024 | clinicaltrials |
| NCT02222272 | Effect of 2nd Gen TKI in CML | completed | — | 432 | European Society for Blood and Marrow TransplantationNETWORK | 9 | Feb 20, 2024 | clinicaltrials |
| NCT03996096 | Tyrosine Kinase Inhibitor Withdrawal Syndrome in CML Patients: Observatory Trial Studying the Biological Factors.(KIWIS) | completed | — | 50 | University Hospital, CaenOTHER | 1 | Feb 14, 2024 | clinicaltrials |
| NCT04169022 | AML Cell Immunotherapy Using Chimeric Antigen Receptor T-cells(CAR-LAM) | completed | N/A | 86 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Feb 12, 2024 | clinicaltrials |
| NCT01735955 | Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study | completed | Phase 4 | 57 | Novartis PharmaceuticalsINDUSTRY | 16 | Feb 8, 2024 | clinicaltrials |
| NCT02057185 | Occupational Status and Hematological Disease(EMATO0113) | completed | — | 141 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT03672695 | Phase I Dose Escalation Study of Intravenously Administered S64315 in Combination With Orally Administered Venetoclax in Patients With Acute Myeloid Leukaemia. | completed | Phase 1 | 37 | Institut de Recherches Internationales ServierOTHER | 3 | Feb 5, 2024 | clinicaltrials |
| NCT02473146 | Gemtuzumab Ozogamicin+Cytarabine vs Idarubicin+Cytarabine in Elderly Patients With AML.Mylofrance 4(ALFA1401) | completed | Phase 2 / Phase 3 | 225 | Versailles HospitalOTHER | 1 | Feb 2, 2024 | clinicaltrials |
| NCT01041508 | Clofarabine and Low Dose Total Body Irradiation as a Preparative Regimen for Stem Cell Transplant in Leukemia. | completed | Phase 1 | 18 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 1 | Feb 1, 2024 | clinicaltrials |
| NCT01497002 | Comparison of the OSHO Protocol to a Standard Arm Protocol of the German AML Intergroup in Patients With AML>60a(AML2004) | completed | Phase 3 | 1,222 | University of LeipzigOTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT01904136 | Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia | completed | Phase 1 / Phase 2 | 54 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT02367456 | A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients(BRIGHT 1012) | completed | Phase 1 | 73 | PfizerINDUSTRY | 6 | Jan 19, 2024 | clinicaltrials |
| NCT02461537 | Impact of Remission Induction Chemotherapy Prior to Allogeneic SCT in Relapsed and Poor-response Patients With AML(ETAL3-ASAP) | completed | Phase 3 | 281 | DKMS gemeinnützige GmbHOTHER | 1 | Jan 19, 2024 | clinicaltrials |
| NCT06211452 | Comparison of Consolidation Strategies for Pediatric Patients With Acute Myeloid Leukemia | completed | Phase 3 | 258 | Grupo Argentino de Tratamiento de la Leucemia AgudaOTHER | 0 | Jan 18, 2024 | clinicaltrials |
| NCT03833180 | A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001) | completed | Phase 1 | 91 | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 1 | Jan 12, 2024 | clinicaltrials |
| NCT01394640 | Immunologic Response After Pandemic Influenza A (H1N1) Vaccine in Onco- Hematologic Patients | completed | — | 124 | Paolo CorradiniOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT03128359 | High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant | completed | Phase 2 | 38 | City of Hope Medical CenterOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT02789254 | FLYSYN in MRD Positive AML(FLYSYN-101) | completed | Phase 1 / Phase 2 | 31 | Synimmune GmbHINDUSTRY | 1 | Dec 28, 2023 | clinicaltrials |
| NCT02626338 | Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML | completed | Phase 1 / Phase 2 | 16 | Arog Pharmaceuticals, Inc.INDUSTRY | 1 | Dec 20, 2023 | clinicaltrials |
| NCT02400255 | Crenolanib Maintenance Following Allogeneic Stem Cell Transplantation in FLT3-positive Acute Myeloid Leukemia Patients | completed | Phase 2 | 30 | Arog Pharmaceuticals, Inc.INDUSTRY | 1 | Dec 18, 2023 | clinicaltrials |
| NCT03734601 | Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation | completed | Phase 2 | 22 | Stanford UniversityOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT05444972 | A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Myelofibrosis Through Chart Review(METER) | completed | — | 998 | AbbVieINDUSTRY | 14 | Dec 11, 2023 | clinicaltrials |
| NCT06159816 | PREVALENCE STUDY OF PNH CLONES IN PATIENTS WITH NEOPLASIES | completed | — | 300 | AUSL Romagna RiminiOTHER | 1 | Dec 7, 2023 | clinicaltrials |
| NCT02509546 | 8-Chloroadenosine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 20 | City of Hope Medical CenterOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT00697684 | Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant | completed | Phase 1 | 29 | Beth Israel Deaconess Medical CenterOTHER | 1 | Nov 28, 2023 | clinicaltrials |
| NCT06148493 | Real-World Usage of Asciminib Among Patients With Chronic Myeloid Leukemia in Chronic Phase in the United States Using a Large Claims Database | completed | — | 425 | Novartis PharmaceuticalsINDUSTRY | 1 | Nov 28, 2023 | clinicaltrials |
| NCT03455517 | Activity and Safety of Front-line Venetoclax and Rituximab in Young and Fit Patients With Chronic Lymphocytic Leukemia(VeRitAs) | completed | Phase 2 | 77 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Nov 24, 2023 | clinicaltrials |
| NCT01523223 | Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies | completed | Phase 1 | 16 | Robert LowskyOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT02543879 | Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies | completed | Phase 1 | 94 | Forma Therapeutics, Inc.INDUSTRY | 1 | Nov 21, 2023 | clinicaltrials |
| NCT03961919 | Phase II Trial in Elderly Patients With AML or MDS in Complete Remission Not Eligible for Allogenic Transplant(FLAT-Auto) | completed | Phase 2 | 15 | Ciceri FabioOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT03298984 | Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML). | completed | Phase 1 | 32 | Sumitomo Pharma America, Inc.INDUSTRY | 1 | Nov 15, 2023 | clinicaltrials |
| NCT02498665 | A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies | completed | Phase 1 | 24 | Sumitomo Pharma America, Inc.INDUSTRY | 1 | Nov 14, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Apr 17, 2024source: clinicaltrials